Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Tomoko Freshwater"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Oncolytic viruses (OVs) represent a novel therapeutic strategy in oncology due to their capability to selectively infect and replicate in cancer cells, triggering a direct and/or immune-induced tumor lysis. However, the mechanisms gover
Externí odkaz:
https://doaj.org/article/44e6e660fac84b639bdd27331dee5f82
Autor:
Zinnia P. Parra-Guillen, Tomoko Freshwater, Youfang Cao, Kapil Mayawala, Sara Zalba, Maria J. Garrido, Dinesh de Alwis, Iñaki F. Troconiz
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
V937 is an investigational novel oncolytic non-genetically modified Kuykendall strain of Coxsackievirus A21 which is in clinical development for the treatment of advanced solid tumor malignancies. V937 infects and lyses tumor cells expressing the int
Externí odkaz:
https://doaj.org/article/fe7a797feed243a7b7e33bf75654da34
Autor:
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the developm
Externí odkaz:
https://doaj.org/article/3069c7c4e0f64562b9cab9bff16d3f3d
Autor:
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies;
Externí odkaz:
https://doaj.org/article/182d21e5687543179e830a09e90b9fdf
Autor:
Zinnia P Parra‐Guillén, Aymara Sancho‐Araiz, Kapil Mayawala, Sara Zalba, Maria J Garrido, Dinesh de Alwis, Iñaki F. Troconiz, Tomoko Freshwater
Publikováno v:
Clinical Pharmacology & Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bdfcb753c6cb6ff10d883fd390c210c
https://doi.org/10.1002/cpt.2937
https://doi.org/10.1002/cpt.2937
Autor:
Anastasios Stathis, Anthony W. Tolcher, Judy S. Wang, Daniel J. Renouf, Lin-Chi Chen, Leah H. Suttner, Tomoko Freshwater, Andrea L. Webber, Tapan Nayak, Lillian L. Siu
Publikováno v:
Investigational New Drugs.
Aim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2) plus selumetinib (mitogen-activated extracellular signal-regulated kinase 1/2 inhibitor) in patients with advanced solid tumors. Methods: This phase 1b,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652b75f884eb5cff650e8062bfcbd68c
https://doi.org/10.1007/s10637-022-01326-3
https://doi.org/10.1007/s10637-022-01326-3
Autor:
Kathleen Moore, Eric H. Rubin, Shelonitda Rose, Jingjun Qiu, Ji Liu, Mark A. Lee, Tomoko Freshwater, Michael Tracy, Naomi Laing, Robert M. Wenham, Johanne I. Weberpals, Denise Uyar, Diane Provencher, Frederik Marmé, Marcia Hall, Eva-Maria Grischke, Maria Estevez-Diz, Amit M. Oza
Supplementary material and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38da5e6e6c6f6147a1c2587f817f6485
https://doi.org/10.1158/1078-0432.22474871.v1
https://doi.org/10.1158/1078-0432.22474871.v1
Autor:
Kathleen Moore, Eric H. Rubin, Shelonitda Rose, Jingjun Qiu, Ji Liu, Mark A. Lee, Tomoko Freshwater, Michael Tracy, Naomi Laing, Robert M. Wenham, Johanne I. Weberpals, Denise Uyar, Diane Provencher, Frederik Marmé, Marcia Hall, Eva-Maria Grischke, Maria Estevez-Diz, Amit M. Oza
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2904c5ffb104f34aa297ea68c6f981a0
https://doi.org/10.1158/1078-0432.22474877
https://doi.org/10.1158/1078-0432.22474877
Autor:
Kathleen Moore, Eric H. Rubin, Shelonitda Rose, Jingjun Qiu, Ji Liu, Mark A. Lee, Tomoko Freshwater, Michael Tracy, Naomi Laing, Robert M. Wenham, Johanne I. Weberpals, Denise Uyar, Diane Provencher, Frederik Marmé, Marcia Hall, Eva-Maria Grischke, Maria Estevez-Diz, Amit M. Oza
Purpose:Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy, would enhance efficacy versus placebo in TP53-mutated ovarian cancer.Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ed41364d68ed987d2532748714770b
https://doi.org/10.1158/1078-0432.c.6528926.v1
https://doi.org/10.1158/1078-0432.c.6528926.v1
Autor:
Kathleen Moore, Eric H. Rubin, Shelonitda Rose, Jingjun Qiu, Ji Liu, Mark A. Lee, Tomoko Freshwater, Michael Tracy, Naomi Laing, Robert M. Wenham, Johanne I. Weberpals, Denise Uyar, Diane Provencher, Frederik Marmé, Marcia Hall, Eva-Maria Grischke, Maria Estevez-Diz, Amit M. Oza
Supplementary Figure 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d79bae918684a7a057155f804ef7959
https://doi.org/10.1158/1078-0432.22474874.v1
https://doi.org/10.1158/1078-0432.22474874.v1